Is the Value Premium Dead? What 90 Years of Data Actually Shows

"Value investing is dead." You've probably read that headline. Between 2010 and 2021, it appeared in Bloomberg, the Financial Times, and dozens of investment research reports. Major hedge funds questioned whether the value premium — one of the most well-documented anomalies in academic finance — had been arbitraged away forever.

Then 2022 happened. Value stocks outperformed growth by more than 20 percentage points in a single year. Suddenly the obituaries disappeared.

So is value investing dead, or was the death narrative itself the real mistake? This article examines 90 years of Fama-French factor data, the mechanisms behind the value premium, what drove its collapse in the 2010s, and why the reversal in 2022 wasn't a surprise to anyone who read the research carefully.

Disclaimer: This article is for informational and educational purposes only. It does not constitute financial advice, investment advice, or a recommendation to buy or sell any security. Past performance does not guarantee future results. All investing involves risk.

What Is the Value Premium?

Before asking whether it's dead, we need to define what "value" means in an academic context — because it's used loosely in investing discourse.

Value investing means buying stocks trading at a discount to intrinsic value. Classically defined by Benjamin Graham and popularized by Warren Buffett, value investors look for businesses where the current market price is less than what the company is fundamentally worth — measured by earnings, book value, cash flow, or other metrics. The key metrics: low price-to-earnings (P/E) ratio, low price-to-book (P/B) ratio, low price-to-sales ratio, and often higher dividend yields.

For academic purposes — which is what factor research measures — value vs. growth maps to low P/B stocks vs. high P/B stocks. You can use the Graham Number Calculator to estimate intrinsic value for individual stocks using the same principles that underpin academic value definitions.

Growth investing means buying stocks expected to grow earnings and revenue significantly faster than the overall market — typically tech, biotech, software, and consumer disruptors. Growth stocks often trade at high P/E multiples because investors are pricing in future earnings that don't yet exist.

The confusion: many investors conflate "growth" with "quality" or "momentum." A company can be both high-quality and undervalued (Buffett's evolved approach). But for factor-based comparison, value vs. growth is operationalized as low P/B vs. high P/B.

The Fama-French Foundation: The Value Premium Is Real

The foundational research on this question comes from Eugene Fama and Kenneth French, two University of Chicago economists whose work reshaped academic finance. Their landmark 1992 paper documented what became known as the value premium: low price-to-book stocks (value) systematically outperformed high price-to-book stocks (growth) over long periods.

Their three-factor model added value (HML — "High Minus Low" book-to-market) and size (SMB — "Small Minus Big") to the traditional single-factor CAPM model. The implication: owning value stocks delivered excess returns over the market that couldn't be explained by market beta alone.

The data behind this finding spans 90+ years of U.S. stock market history. From 1926 through the early 2000s, the value premium in the Fama-French dataset averaged roughly 4–5% per year over growth. Not in every year — value could underperform for stretches — but over rolling 10- and 20-year periods, value stocks consistently beat the market and consistently beat growth stocks.

Why does the premium exist? Two main explanations compete:

Risk-based explanation (Fama-French's view): Value stocks are riskier — they're often distressed, financially stressed, or operating in difficult industries. The excess return compensates for bearing that risk. The premium is real but earned by accepting uncertainty.

Behavioral explanation (Lakonishok, Shleifer, Vishny): Investors are systematically too pessimistic about value stocks and too optimistic about growth stocks. The excess return comes from mean-reversion as overly pessimistic valuations correct. This is a mispricing story, not a risk story.

Both explanations have empirical support, and both suggest the value premium should persist. Neither predicts it will disappear permanently. If you're new to these concepts, the value investing for beginners guide covers the foundational principles in plain language.

The 2010–2021 Decade: "Value Is Dead"

The decade following the Global Financial Crisis was brutal for value investors. From 2010 through 2021, U.S. growth stocks — particularly large-cap technology companies — delivered extraordinary returns. The Russell 1000 Growth index compounded at roughly 17% per year during this period. The Russell 1000 Value index compounded at roughly 11%. A gap of 6% annually, compounded over 11 years, produced dramatically different outcomes.

This wasn't a temporary blip. It was persistent, broad, and painful. By 2020, major institutional asset managers were publishing research asking whether the value factor had been "arbitraged away." AQR Capital Management — one of the world's most sophisticated quant shops and a major proponent of factor investing — reported its worst decade on record, driven largely by value's underperformance.

What actually drove growth's dominance?

Several structural factors worked against value and for growth during this period:

1. Zero interest rates. When discount rates approach zero, the present value of future cash flows becomes enormous. Growth stocks are valued on earnings far in the future; low rates made those future earnings worth much more in present value terms. Value stocks with current earnings didn't benefit nearly as much.

2. Winner-take-all tech economics. The major growth companies of the 2010s — Google, Apple, Amazon, Meta, Microsoft — achieved genuinely extraordinary competitive positions. Their dominance wasn't fully priced in when they appeared "expensive" in 2012; they grew into and beyond their valuations.

3. Sector composition problems. Classic value indices were full of banks, energy companies, and retailers — industries facing real structural headwinds from fintech, shale disruption, and e-commerce. Growth indices were dominated by technology. The relative performance reflected real differences in business quality, not just valuation.

4. Globalization and deflationary forces. The broader macro environment suppressed inflation and kept rates low, systematically benefiting long-duration assets (growth stocks are, in effect, long-duration assets).

These are legitimate structural explanations — but none of them suggest the value premium is permanently dead. They explain why value underperformed during a specific set of macro conditions. The mechanism, not the premium itself, was broken.

2022: The Data Answers the Question

The answer to "is value investing dead?" came swiftly and definitively in 2022.

When the Federal Reserve began its most aggressive rate-hiking cycle in 40 years — raising the federal funds rate from near-zero to over 4% in under 12 months — the mechanics that had powered growth stocks ran in reverse. Rising discount rates crushed the present value of distant future earnings. Speculative growth companies with no current profits saw their stocks fall 60–80%. The Ark Innovation ETF (ARKK), a proxy for high-growth speculation, fell approximately 75% from its 2021 peak.

Value stocks, particularly financial stocks (which benefit from higher rates) and energy companies (which benefited from inflation and supply constraints), dramatically outperformed. In 2022:

• Russell 1000 Value: approximately -7.5%
• Russell 1000 Growth: approximately -29.1%
• Difference: ~22 percentage points in a single year

In a single year, value recovered several years of relative underperformance. Fama-French factor researchers noted that the 2022 reversal was one of the strongest single-year value premium realizations in the dataset's history.

This vindicated the risk-based explanation in one specific sense: value stocks were indeed less sensitive to the dramatic repricing that occurred when the cost of capital normalized. The "dead" premium came roaring back the moment the conditions that suppressed it changed.

What the Full 90-Year Dataset Actually Shows

Setting aside the decade-by-decade swings, here's what the complete body of evidence supports:

1. Value has outperformed growth over the very long run — but the premium is not guaranteed in any 10-year window. The Fama-French data going back to 1926 shows a persistent value premium. But individual decades show large swings in both directions. Value outperformed in the 1970s, 1980s, and 2000s. Growth dramatically outperformed in the 1990s and 2010s. The premium exists but requires patience measured in decades, not years.

2. The value premium is stronger internationally and in small caps. AQR and others have shown that the value factor is more robust outside the U.S. (where information advantages are harder to arbitrage) and among small-cap stocks. Large-cap U.S. value vs. growth is the most efficiently priced comparison; international and small-cap value shows stronger persistent premiums.

3. Quality matters. Modern factor research distinguishes between "cheap" and "quality cheap." Value stocks that are cheap because of financial distress often don't recover. Value stocks that are cheap relative to their actual earning power — quality businesses at fair or discounted prices — show the strongest long-term returns. This is Buffett's contribution beyond Graham: screen for quality, then screen for price.

4. Neither approach eliminates the need for patience. Both value and growth investors experience painful multi-year stretches where their approach lags the market. Growth investors in 2000–2002 and 2022 saw devastating losses. Value investors in 2017–2020 felt irrelevant. Long-term outperformance requires surviving short-term underperformance — psychologically and financially.

Growth's Real Advantage: Single-Stock Asymmetry

One legitimate advantage of growth investing deserves acknowledgment: asymmetric upside.

A value stock that doubles from a deeply discounted price is a success. A growth stock in a genuinely transformative business can return 10x, 50x, or 100x if the thesis is correct. Amazon traded at a P/E ratio that looked insane in 2001 — and returned 200x from that point over the next 20 years. No value screen would have surfaced Amazon as an investment.

The counterargument: for every Amazon, there are thousands of "transformative" companies that burned investors' capital entirely. The survivorship bias in growth investing case studies is enormous. We remember the 100x winners; we forget the 500 companies that lost 90%.

The data on individual stock selection (vs. factor-based portfolio construction) is less clear. Some skilled growth investors have genuinely added alpha. But the evidence that the average growth investor outperforms the average value investor — or that growth factors systematically beat value factors — over long periods is not strong.

The Practical Conclusion: Value as a Foundation, Quality as a Filter

For most individual investors, the research suggests a pragmatic synthesis:

Own the value factor as a tilt, not an absolute. A portfolio with a modest tilt toward lower-P/E, lower-P/B stocks has historically delivered somewhat better risk-adjusted returns than a pure market cap-weighted index. This doesn't require abandoning diversification or ignoring great businesses.

Filter for quality within value. The strongest results in the academic literature come from value + profitability factors combined. Cheap stocks of strong businesses outperform cheap stocks of struggling businesses over time. This is why Buffett's concentrated approach on "wonderful companies at fair prices" has worked — it's implicitly combining value and quality screens.

Extend your time horizon. The value premium has rarely delivered on a 3-year horizon. On 20-year horizons, the evidence is much stronger. If your investment horizon is shorter than a decade, factor tilts are less relevant than asset allocation and cost management.

Don't get captured by a narrative. "Value is dead" in 2021 and "growth is dead" in 2022 were both wrong. Markets reprice assets continuously; no approach permanently dominates. The investors who suffered most in both environments were those who capitalized on momentum at the extreme — buying high-multiple growth stocks at peak valuations in late 2021, or abandoning the market entirely after the 2022 crash.

Ready to put this into practice? Use our stock screener to find value stocks trading below their intrinsic worth today — filtered by P/E, P/B, dividend yield, and other fundamental metrics. Or run any individual stock through the Graham Number Calculator to get a quick conservative estimate of intrinsic value.

Where Do We Stand in 2026?

As of early 2026, value stocks remain reasonably priced relative to their long-term averages. The extreme P/E dispersion between value and growth that characterized 2020–2021 has moderated but not disappeared. Large-cap technology companies still trade at significant premiums to the broader market.

This is not a prediction — markets can sustain high valuations for years, as the 2010s demonstrated. But it does suggest that the environment for value investing in 2026 is more favorable than it was in 2019, when value was historically cheap relative to growth and the premium was overdue to reassert itself.

The Bottom Line: Is Value Investing Dead?

No. The value premium is not dead.

The Fama-French data hasn't changed. The mechanisms that drive the value premium — mean reversion of pessimistic expectations, compensation for distress risk, or some combination — remain in place. The 2010–2021 underperformance had a clear structural explanation rooted in zero interest rates and winner-take-all tech dynamics. The 2022 reversal demonstrated that those mechanisms were suppressed, not eliminated.

The decade of underperformance and the sharp 2022 reversal together tell a consistent story: is value investing dead is a question that flares up every time growth outperforms for an extended stretch — and the data consistently answers it the same way. The premium is real, it requires patience, and it rewards those who don't abandon it at the worst possible moment.

Patience, valuation discipline, and quality screening remain the foundation of sound long-term investing — regardless of what the most recent 12 months suggest.